tuneTypical Dose
Match the dose and form to a studied syrup or capsule product rather than generic elderberry labeling
Botanical
Elderberry
Sambucus nigra
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
The evidence focuses on early acute illness use over several days.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Elderberry may modestly reduce upper-respiratory symptom duration and severity after illness starts, but prevention evidence is weak and it should not be treated like a proven antiviral.
Elderberry is popular for immune support, but the strongest human evidence is narrower than that label suggests. The better-supported use case is modest symptomatic relief in viral upper-respiratory illness, especially when started early. Prevention evidence is weaker. A short 2024 metabolic crossover trial suggests elderberry juice can shift gut-microbiota and meal-challenge markers, but that does not change the core respiratory framing. Elderberry is better framed as a possible symptom-support supplement than as an immune booster that stops infection or replaces standard care.
Elderberry is usually discussed in relation to polyphenols and antiviral or immunomodulatory activity. The useful human evidence is symptom oriented and does not justify broad claims about preventing infection or broadly enhancing immunity.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Possible reduction in upper-respiratory symptom duration and severity
Secondary Outcomes
- Stronger evidence for treatment use than for prevention
- Weak support for generic immune-boosting claims
Safety
Contraindications and Interactions
Contraindications
- Use of raw or improperly prepared elderberry plant material
Side effects
- Mild GI upset
Interactions
No entries provided
Avoid if
- You are using it instead of indicated antiviral or medical care
- You are relying on raw elderberry preparations
Evidence
Study-level References
eld-SRC-001Systematic review and meta-analysis
Sourceopen_in_newHawkins J, Baker C, Cherry L, Dunne E. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials. Complement Ther Med. 2019;42:361-365. doi:10.1016/j.ctim.2018.12.004. PMID:30670267.
Population: Adults from randomized controlled trials of elderberry for influenza-like illness or common cold symptoms.
Dose protocol: Mixed elderberry syrup and capsule protocols across 4 RCTs
Key findings: Reduced upper-respiratory symptom duration and severity.
Notes: Best pooled efficacy anchor.
Paper content
This is the main pooled evidence anchor for elderberry. It supports a reduction in upper respiratory symptom burden, but the trial set is small and made up of product-specific studies. The evidence is stronger for symptomatic use after illness onset than for reliable prevention.
eld-SRC-002Randomized controlled trial
Sourceopen_in_newZakay-Rones Z, Thom E, Wollan T, Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 2004;32(2):132-140. doi:10.1177/147323000403200205. PMID:15080016.
Population: Adults with influenza-like illness of 48 hours or less duration.
Dose protocol: Elderberry syrup 15 mL four times daily for 5 days
Key findings: Earlier symptom relief in influenza-like illness.
Notes: Classic early-treatment trial.
Paper content
This is the classic positive elderberry influenza-treatment trial. It suggests meaningful symptom shortening when treatment is started early, but the sample was small and the product was proprietary syrup. The study is useful, but it should not be treated as proof that elderberry broadly treats viral respiratory illness.
eld-SRC-003Randomized controlled trial
Sourceopen_in_newTiralongo E, Wee SS, Lea RA. Elderberry supplementation reduces cold duration and symptoms in air-travellers: A randomized, double-blind placebo-controlled clinical trial. Nutrients. 2016;8(4):182. doi:10.3390/nu8040182. PMID:27023596.
Population: International air travelers.
Dose protocol: Travel-period elderberry capsules using a product-specific regimen
Key findings: Reduced cold duration and severity among participants who became ill, without clear prevention benefit.
Notes: Useful separation of prevention versus treatment framing.
Paper content
This is a useful elderberry cold study because it separates prevention from symptom modification. It did not clearly prevent colds, but among people who became sick it reduced duration and severity. That fits the broader pattern of elderberry being more plausible for symptomatic support than for prevention.
eld-SRC-004Systematic review
Sourceopen_in_newUlbricht C, Basch E, Cheung L, et al. Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review. J Med Virol. 2021;93(6):3838-3848. doi:10.1002/jmv.26853. PMID:33827515.
Population: Participants from randomized trials of elderberry for prevention or treatment of viral respiratory illnesses.
Dose protocol: Review of existing clinical elderberry trials
Key findings: Treatment evidence stronger than prevention evidence, with no clear cytokine-storm signal.
Notes: Useful framing review.
Paper content
This review is useful because it tempers two common elderberry mistakes. First, the treatment evidence is stronger than the prevention evidence. Second, the often-repeated fear that elderberry predictably worsens cytokine-driven illness is not supported by the available human data. That still does not turn elderberry into a high-confidence antiviral treatment.
eld-SRC-005Randomized controlled trial.
Sourceopen_in_newGoh KM, Tan ESS, Lim CSY, et al. Effect of Dietary Supplementation with Lutein, Zeaxanthin, and Elderberries on Dry Eye Disease (DED) and Immunity: A Randomized Controlled Trial. Nutrients. 2024;16(24):4366. doi:10.3390/nu16244366. PMID:39770987.
Population: Adults with dry eye disease symptoms.
Dose protocol: 100 mg elderberry extract with lutein and zeaxanthin daily for 20 days
Key findings: OSDI dry eye score improved 52.2%, visual comfort improved 26.7%. Immune status improvement was not significant versus placebo.
Notes: Combination formulation prevents isolating elderberry contribution. Novel dry eye endpoint. Short duration.
Paper content
This RCT tested a combination of lutein, zeaxanthin, and 100 mg elderberry extract in 110 adults with dry eye disease over 20 days. The OSDI symptom score decreased by 52.2% and visual comfort improved by 26.7%, both significantly better than placebo. The immune status questionnaire showed a non-significant 15.9% improvement. While the dry eye results are encouraging, the combination formulation makes it impossible to isolate the elderberry contribution from the carotenoid components. The short 20-day duration also limits conclusions about sustained benefit. The study adds a novel endpoint (dry eye) to the elderberry literature but does not change the core respiratory evidence framing.
eld-SRC-006Randomized, placebo-controlled crossover trial
Sourceopen_in_newTeets C, Ghanem N, Ma G, Minj J, Perkins-Veazie P, Johnson SA, Etter AJ, Carbonero FG, Solverson PM. A One-Week Elderberry Juice Intervention Augments the Fecal Microbiota and Suggests Improvement in Glucose Tolerance and Fat Oxidation in a Randomized Controlled Trial. Nutrients. 2024;16(20):3555. doi:10.3390/nu16203555. PMID:39458549.
Population: Overweight or obese adults without chronic illness.
Dose protocol: Anthocyanin-dense elderberry juice twice daily for one week in a crossover design
Key findings: Improved meal-challenge glucose response and fat oxidation while shifting fecal microbiota composition in overweight adults.
Notes: Interesting metabolic signal, but the trial was tiny, short, and juice specific. It does not change elderberry's core respiratory framing.
Paper content
This short crossover RCT moved elderberry beyond respiratory endpoints and tested anthocyanin-dense elderberry juice in 18 overweight or obese adults over two 1-week intervention periods. Elderberry juice shifted fecal microbiota composition, reduced post-meal glucose response, and increased fat oxidation during both a meal challenge and moderate exercise. The findings are interesting because they suggest elderberry juice can have measurable metabolic effects over a very short interval, but the sample was tiny, the intervention was juice-specific, and the trial was not designed to establish durable clinical benefit. It should be treated as exploratory metabolic evidence rather than as a reason to reposition elderberry away from its core symptom-support respiratory framing.